Emergent Biosolutions
EBS
161 hedge funds and large institutions have $176M invested in Emergent Biosolutions in 2025 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 53 increasing their positions, 40 reducing their positions, and 28 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 40
25% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 28
3% more funds holding
Funds holding: 156 → 161 (+5)
2.57% more ownership
Funds ownership: 64.1% → 66.68% (+2.6%)
1% less call options, than puts
Call options by funds: $944K | Put options by funds: $956K
47% less capital invested
Capital invested by funds: $332M → $176M (-$156M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$8.45M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
+$6.7M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$5.23M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.08M |
| 5 |
PGCM
Prescott Group Capital Management
Tulsa,
Oklahoma
|
+$3.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$6.56M |
| 2 |
Charles Schwab
San Francisco,
California
|
-$5.85M |
| 3 |
Two Sigma Investments
New York
|
-$3.72M |
| 4 |
Morgan Stanley
New York
|
-$2.98M |
| 5 |
State Street
Boston,
Massachusetts
|
-$2.09M |
EBS Hedge Fund Activity: Q1 2025 in Review
161 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q1 2025, worth a combined $176M — down 47% from $332M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new EBS positions and 28 closed out — a net gain of 7 holders — while 53 added to existing stakes and 40 trimmed.
The largest buyer was Millennium Management, adding an estimated $8.45M. The largest seller was Invesco, cutting an estimated $6.56M.
- 161 institutional investors held Emergent Biosolutions (EBS) as of Q1 2025, up from 156 in Q4 2024.
- Funds reported $176M of Emergent Biosolutions stock for Q1 2025, down 47% quarter-over-quarter.
- 35 funds opened new Emergent Biosolutions positions in Q1 2025 and 28 closed out, a net change of +7 holders.
- The largest Emergent Biosolutions buyer in Q1 2025 was Millennium Management, an estimated $8.45M added.
- The largest Emergent Biosolutions seller in Q1 2025 was Invesco, an estimated $6.56M sold.
Based on aggregated 13F filings for Q1 2025.